Vertex Shares Slide After Combined Cystic Fibrosis Therapy Disappoints in Preliminary Data
Cystic Fibrosis, News
Shares of Vertex Pharmaceuticals Inc. fell sharply in the wake of disappointing results of the company’s drug combination of experimental drug VX-661 with FDA-approved Kalydeco. The company stated that its investigational cystic fibrosis drug combination drug did ... Read more